AstraZeneca Introduces Evinova to Advance Global Digital Health Solutions for Enhanced Clinical Trials

Evinova focuses on introducing globally-used digital solutions from AstraZeneca to optimise clinical trials, aiming to streamline new medicine development, improve patient care accessibility, and ease the burden on health systems.

AstraZeneca has unveiled Evinova, a digital health solutions provider catering to the evolving needs of healthcare professionals, regulators, and patients. This initiative, backed by long-term support from AstraZeneca and strategic collaborations with Parexel and Fortrea, positions Evinova to deliver globally scaled digital products and services to the life sciences and healthcare sector.

Evinova's primary focus is on bringing established and scaled digital technology solutions to market, already in use globally by AstraZeneca, to optimise clinical trial design and delivery. This strategic approach aims to streamline the development of new medicines, enhance patient care accessibility, and alleviate the burden on health systems.

Additionally, Evinova is exploring opportunities in digital remote patient monitoring and

digital therapeutics, presenting a pipeline of digital innovations in these domains.

The core of Evinova's offerings lies in the collaboration with AstraZeneca, drawing on the pharmaceutical giant's extensive experience developing novel therapeutics and insights gathered from thousands of patients and clinical researchers.

Evinova aims to extend these established technology solutions to pharmaceutical companies, biotechs, and Clinical Research Organisations (CROs) globally, leveraging technologies employed in multiple AstraZeneca-sponsored clinical trials across 40 countries.

Commenting on the same, Pascal Soriot, CEO of AstraZeneca, said, "The future of medicine development can be accelerated with digital solutions. We believe Evinova's combination of scientific expertise and track record in developing AI-enabled digital technologies at scale, provides a real opportunity to fundamentally improve patient care, drive healthcare transformation and reduce carbon emissions."

Further, Cristina Duran, president of Evinova, highlighted the importance of offering digital solutions that seamlessly transcend pharmaceuticals, comprehensively supporting patients and healthcare professionals.

Additionally, leading CROs, Parexel and Fortrea, also entered agreements to offer Evinova's digital health solutions to their extensive customer base. To propel industry adoption, Evinova has further collaborated with Accenture and Amazon Web Services, aiming to sustain and expand the global reach of its digital products.

Evinova combines clinical and regulatory expertise gained at AstraZeneca with deep knowledge in digital technology, covering strategy and development, digital product development, data science and AI, user experience design, and behavioural science.

Beyond digital solutions, Evinova plans to offer custom scientific solutions, including remote patient monitoring, novel endpoint solutions, trial design, and consulting services.

Digital health technologies are recognised as a solution to reduce healthcare costs while improving patient experience and outcomes. Evinova's entrance into this burgeoning market aligns with the global trend toward digital health interventions.

With the potential to save the US healthcare system nearly $500 billion, according to McKinsey estimates, digital health is a sizable and growing market, with a projected value exceeding $900 billion by 2032.

In another development, in collaboration with a clinical-stage biotechnology company, Cellectis, AstraZeneca inked an investment agreement to accelerate the development of next-generation therapeutics in areas of high unmet need, including oncology, immunology and rare diseases.

As per the agreement, AstraZeneca will leverage Cellectis' proprietary gene editing technologies and manufacturing capabilities to design novel cell and gene therapy products, strengthening AstraZeneca's growing offering in this space.